Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$3.11 -8.5%	$1.84	$0.98 ▼ $3.44	$125.38M	0.07	29,274 shs	213,609 shs
DTIL Precision BioSciences	$4.70 -4.1%	$5.05	$3.61 ▼ $11.09	$52.12M	1.48	187,243 shs	180,458 shs
MDCX Medicus Pharma	$2.58 +0.4%	$4.26	$1.80 ▼ $8.94	$35.02M	N/A	417,080 shs	120,773 shs
NRSN NeuroSense Therapeutics	$2.45 +2.1%	$1.45	$0.51 ▼ $2.60	$33.48M	1.62	274,859 shs	325,122 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	+9.89%	+85.01%	+94.38%	+9.51%
DTIL Precision BioSciences	0.00%	-6.56%	-3.69%	-13.76%	-53.47%
MDCX Medicus Pharma	0.00%	-7.53%	-66.10%	-22.29%	+257,999,900.00%
NRSN NeuroSense Therapeutics	0.00%	+2.94%	+50.31%	+128.97%	+166.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	4.0698 of 5 stars	3.5	3.0	0.0	4.6	0.0	1.7	1.3
MDCX Medicus Pharma	1.7402 of 5 stars	3.8	0.0	0.0	0.0	2.0	0.8	0.0
NRSN NeuroSense Therapeutics	1.7469 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	900.00% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	810.85% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	471.43% Upside

Current Analyst Ratings Breakdown

Latest NRSN, MDCX, DTIL, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/14/2025	MDCX Medicus Pharma	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.75M	71.65	N/A	N/A	($0.37) per share	-8.41
DTIL Precision BioSciences	$68.70M	0.76	N/A	N/A	$6.87 per share	0.68
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	6/27/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	6/24/2025 (Estimated)

Latest NRSN, MDCX, DTIL, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/24/2025	Q1 2025	NRSN NeuroSense Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
4/7/2025	Q4 2024	NRSN NeuroSense Therapeutics	-$0.12	-$0.06	+$0.06	-$0.06	N/A	N/A
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	2.49	2.49
DTIL Precision BioSciences	0.45	6.62	6.62
MDCX Medicus Pharma	N/A	1.53	1.53
NRSN NeuroSense Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
DTIL Precision BioSciences	37.99%
MDCX Medicus Pharma	N/A
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
DTIL Precision BioSciences	4.50%
MDCX Medicus Pharma	N/A
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
DTIL Precision BioSciences	200	11.09 million	10.59 million	No Data
MDCX Medicus Pharma	N/A	13.57 million	N/A	N/A
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

NRSN, MDCX, DTIL, and BYSI Headlines

Recent News About These Companies

NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday

June 17 at 1:12 AM | americanbankingnews.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.com

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.com

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.com

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.com

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.com

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

February 19, 2025 | tipranks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

February 4, 2025 | markets.businessinsider.com

NeuroSense regains Nasdaq compliance

January 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, MDCX, DTIL, and BYSI Company Descriptions

BeyondSpring NASDAQ:BYSI

$3.11 -0.29 (-8.53%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.07 -0.04 (-1.29%)

As of 06/18/2025 04:12 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Precision BioSciences NASDAQ:DTIL

$4.70 -0.20 (-4.08%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.86 +0.16 (+3.30%)

As of 06/18/2025 07:48 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Medicus Pharma NASDAQ:MDCX

$2.58 +0.01 (+0.39%)

As of 06/18/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

NeuroSense Therapeutics NASDAQ:NRSN

$2.45 +0.05 (+2.08%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.42 -0.03 (-1.02%)

As of 06/18/2025 07:59 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time